Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANG1005 in HER2-negative breast cancer with leptomeningeal carcinomatosis
NCT03613181Phase 3Unknown
- Sponsor
- Angiochem Inc.
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 3 trial of paclitaxel trevatide in leptomeningeal carcinomatosis (LMC), breast cancer, brain metastases, sponsored by Angiochem Inc.. Status: unknown.
02
Drugs
paclitaxel trevatide
03
Conditions
leptomeningeal carcinomatosis (LMC)breast cancerbrain metastases
Beyond the preview
Go deeper on NCT03613181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613181.